Authors' reply: PSMA-PET: is the time to say goodbye to metabolic radiopharmaceuticals in prostate cancer?
Eur J Nucl Med Mol Imaging
.
2021 Jul;48(8):2307-2308.
doi: 10.1007/s00259-021-05376-2.
Epub 2021 May 4.
Authors
Ian Alberts
1
,
Svenja Elizabeth Seide
2
,
Clemens Mingels
3
,
Karl Peter Bohn
3
,
Kuangyu Shi
3
,
Helle D Zacho
4
,
Axel Rominger
3
,
Ali Afshar-Oromieh
3
Affiliations
1
Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, CH-3010, Bern, Switzerland. ian.alberts@insel.ch.
2
Institute of Medical Biometry and Informatics, University of Heidelberg, Im Neuenheimer Feld 130.3, 69120, Heidelberg, Germany.
3
Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, CH-3010, Bern, Switzerland.
4
Department of Nuclear Medicine and Clinical Cancer Research Center, Aalborg University Hospital, Hobrovej 18-22, DK-9000, Aalborg, Denmark.
PMID:
33948676
DOI:
10.1007/s00259-021-05376-2
No abstract available
Publication types
Letter
Comment
MeSH terms
Glutamate Carboxypeptidase II
Humans
Male
Positron-Emission Tomography
Prostatic Neoplasms* / diagnostic imaging
Radiopharmaceuticals*
Substances
Radiopharmaceuticals
Glutamate Carboxypeptidase II